Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

41.34USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$41.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,843,796
52-wk High
$47.81
52-wk Low
$29.44

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program

* MYLAN RECEIVES TENTATIVE APPROVAL FOR COMBINATION HIV TREATMENT DTG/FTC/TAF UNDER FDA'S PEPFAR PROGRAM

20 Feb 2018

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

13 Feb 2018

UPDATE 2-Novartis gains U.S. approval for delayed MS drug

* U.S. pricing pressure weighing on Sandoz (Adds Teva comment, share price reaction)

13 Feb 2018

BRIEF-Mylan Expands Access To HIV/AIDS Medicines With Launch Of First Generic Sustiva Tablets

* MYLAN EXPANDS ACCESS TO HIV/AIDS MEDICINES WITH LAUNCH OF FIRST GENERIC SUSTIVA® TABLETS

01 Feb 2018

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

29 Jan 2018

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

29 Jan 2018

BRIEF-Tax reform relatively neutral for Mylan-CFO

* SAYS ITS BIOSIMILAR FOR AMGEN'S NEULASTA COULD BE A "MID-YEAR OPPORTUNITY"

10 Jan 2018

BRIEF-Mylan To Complete $1 Billion Share Repurchase Plan

* MYLAN - AS PER AGREEMENT WITH ABBOTT RELATED TO ABBOTT EPD DEAL, ABBOTT NOTIFIED MYLAN IT SOLD REMAINING 20.3 MILLION IN MYLAN SHARES PRIOR TO YEAR-END​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

08 Jan 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

04 Jan 2018

Earnings vs. Estimates